US100 (D1 timeframe)
- Any “scratch” in the report could allow sellers to regain control across equity indices—there is little room for weakness in today’s quarterly release. Nasdaq 100 futures are up nearly 0.3% around 9:30am Poland time and are pushing above the 25,000-point mark.
- The index is currently trading near the 38.2% Fibonacci retracement of the most recent downside impulse. A sustained break above this level—and a move through 25,150—could open the way toward 25,550, where the 61.8% retracement sits. That said, it is difficult to expect a decisive move before Nvidia publishes its results.
- Notably, the index is still relatively close (around 600 points) to the daily EMA200 (red line), which suggests market stress remains elevated. Wall Street caught a breath yesterday after Anthropic announced several strategic partnerships with major US software companies, including Spotify and Salesforce, easing fears of a “total disruption” of their business models.
- This naturally pushed investors back toward a scenario in which companies implement AI into their products rather than compete with it for the same market. However, if those fears re-emerge after today’s NVDA report, the 24,400 area looks like a critical test of the bull trend and a key support zone that the index already rebounded from in early February.
- Overall, key support levels remain 24,750 (23.6% Fibonacci retracement; also reinforced by recent price reactions—lower wicks on the last nine candles) and 24,400 (EMA200). The key resistance remains 25,500, where the 61.8% retracement aligns with the EMA50 (orange line).

Source: xStation5
Market wrap ๐US indices in focus amid strong NFP data and $100 oil
BREAKING: NFP payrolls skyrocket ๐ EURUSD back in red ๐
EURUSD catches breath before NFP ๐
DAX down 12% from all-time high ๐ฉWatch this 2 stocks in April
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.